Anat Loewenstein

TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).

TL;DR: Among patients with macular edema owing to BRVO or CRVO, single and repeated treatment with DEX implant had a favorable safety profile over 12 months.

TL;DR: Ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up, but definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management.

TL;DR: As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema, and anti-vascular endothelial growth factor therapy has emerged as first-line therapy and Steroids have maintained a role in the management of chronically persistent DME.

TL;DR: Bvacizumab was found to be nontoxic to the retina of rabbits based on electrophysiologic studies, and full thickness retinal penetration may explain observed clinical effects of intravitreal bevacIZumab.